Treatment of cervical cancer in 2024 in the highlight of KEYNOTE-A18 study

Professor Remi Nout shares his thoughts on the treatment of cervical cancer in 2024 in the light of KEYNOTE-A18 study.

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

Professor Remi Nout shares his thoughts on the interim results of the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial that were presented during the ESMO Congress 2024.

Breast cancer, early stage highlights of the ESMO 2024 Congress

Professor Ann Partridge shares his thoughts on breast cancer, early stage highlights of the ESMO 2024 Congress.

Setting a new benchmark for ALK+ aNSCLC targeted therapy - report from ESMO2024

Professor Tony S.K. Mok shares his thoughts on setting a new benchmark for ALK+ aNSCLC targeted therapy.

POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC - report from ESMO2024

Professor Dominik P. Modest shares his thoughts on POD1UM-303/InterAACT 2 study, which are potentially practice-changing findings in squamous cell carcinoma of the anal canal.

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC.

PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer

Professor Silke Gillessen presented new results from the PEACE-3 trial at the 2024 ESMO conference. This study indicates that combining Enzalutamide with Radium223 significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases over Enzalutamide alone.

Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

Professor Silke Gillessen discussing results from STAMPEDE trial assessing the addition of metformin to ADT for patients with mHSPC.

Breakthroughs and challenges in the treatment of head and neck cancer

Dr. Robert Sifrer, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ljubljana, believes that the most important breakthrough in the treatment of head and neck cancer patients has been the recent development of immunotherapy, which is also helping patients with advanced stage cancer, and expects the importance of drug therapies to increase in the future. He was also asked about the problems of caring for patients with head and neck cancer in our interview at the International Danube Symposium on Otolaryngology.

HPV-associated head and neck cancers

Professor Thomas Hoffmann, Director of the Department of Otolaryngology and Head and Neck Surgery at the University of Ulm, raises awareness of the growing number of HPV-associated head and neck cancers in our interview. The right combination of treatment modalities - less and less invasive surgical procedures, increasingly precise radiotherapy options and systemic therapies, especially immunotherapies - can make a dramatic difference to disease outcomes, while the role of prophylactic HPV vaccination cannot be overemphasised.

Follicular Lymphoma highlights of the ASH 2023 Congress

Professor Carla Casulo summarizes the most important highlights in the field of Follicular Lymphoma treatment after the 65th American Society of Hematology Annual Meeting.

Highlights of the ASH 2023 Congress

Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting.

Present and future of Multiple Myeloma management

Professor Xavier Leleu explains the present and future of Multiple Myeloma management, how new regiments, new treatments will change how we treat patients.

Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma

Professor Michael Wang explains their findings that combining ibrutinib and venetoclax improves progression-free survival and remission rates in patients with mantle cell lymphoma.

Real-World Outcomes With Brexucabtagene Autoleucel

Professor Swetha Kambhampati on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel.

Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023

Professor on frontline treatment with targeted agents in patients with Chronic Lymphocytic Leukemia.

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates

Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients

Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint

Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)